Standout Papers

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myel... 2016 2026 2019 2022 342
  1. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis (2016)
    Claire Harrison, Alessandro M. Vannucchi et al. Leukemia

Immediate Impact

5 from Science/Nature 64 standout
Sub-graph 1 of 23

Citing Papers

JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
Why do patients with cancer die?
2024 Standout
3 intermediate papers

Works of P. Gopalakrishna being referenced

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
2016 Standout
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
2015

Author Peers

Author Last Decade Papers Cites
P. Gopalakrishna 265 96 467 375 7 602
Marianne Rosamilia 157 116 299 465 6 662
L. Knoops 275 144 415 330 13 612
Teresa Davies 205 86 333 473 9 693
Laurence Reilly 93 194 234 295 7 523
Matthew J. Wong 256 125 182 225 12 587
Mario Lazzarino 250 81 420 502 12 688
A B Deisseroth 109 103 283 430 10 579
Jean Michel Cayuela 130 145 402 470 12 712
Ayalew Tefferi 187 50 447 397 12 574
Joyce Niblack 264 44 447 357 7 545

All Works

Loading papers...

Rankless by CCL
2026